These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30646957)

  • 1. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.
    Newton JM; Hanoteau A; Liu HC; Gaspero A; Parikh F; Gartrell-Corrado RD; Hart TD; Laoui D; Van Ginderachter JA; Dharmaraj N; Spanos WC; Saenger Y; Young S; Sikora AG
    J Immunother Cancer; 2019 Aug; 7(1):216. PubMed ID: 31409394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.
    Shivarudrappa AH; John J; Vashisht M; Ge H; Liu S; Chen J; Siddoway K; Dong R; Chen Z; Wang JH
    Front Immunol; 2024; 15():1405318. PubMed ID: 39055715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma.
    Ryan N; Lamenza F; Shrestha S; Upadhaya P; Springer A; Jordanides P; Pracha H; Roth P; Kumar R; Wang Y; Vilgelm AE; Satoskar A; Oghumu S
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167345. PubMed ID: 38992847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I conventional dendritic cells and CD8
    Kirchner J; Plesca I; Rothe R; Resag A; Löck S; Benešová I; Rupp L; Linge A; Wehner R; Krause M; Schmitz M
    Front Immunol; 2024; 15():1414298. PubMed ID: 38938577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
    Watermann C; Pasternack H; Idel C; Ribbat-Idel J; Brägelmann J; Kuppler P; Offermann A; Jonigk D; Kühnel MP; Schröck A; Dreyer E; Rosero C; Nathansen J; Dubrovska A; Tharun L; Kirfel J; Wollenberg B; Perner S; Krupar R
    Clin Cancer Res; 2021 Jan; 27(2):632-644. PubMed ID: 33109740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
    Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
    J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
    Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
    Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
    Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
    Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
    Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.
    Habu T; Kumagai S; Bando H; Fujisawa T; Mishima S; Kotani D; Nakamura M; Hojo H; Sakashita S; Kinoshita T; Yano T; Mitsunaga S; Nishikawa H; Koyama S; Kojima T
    J Gastroenterol; 2024 Sep; 59(9):798-811. PubMed ID: 38819498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
    Ruffin AT; Li H; Vujanovic L; Zandberg DP; Ferris RL; Bruno TC
    Nat Rev Cancer; 2023 Mar; 23(3):173-188. PubMed ID: 36456755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.